



FREQUENTLY ASKED QUESTIONS

Below are answers to commonly asked questions about the Eversense 365 CGM system. If you have any further questions or would like to speak to us about a media opportunity, then please get in touch with our press team at AscensiaComms@fticonsulting.com

Please note for important safety information, see <https://www.eversenseddiabetes.com/safety-info>

What is the Eversense 365 CGM System?

Eversense 365 is the world's first and only One Year CGM system. It is a highly differentiated CGM system indicated for the management of type 1 and type 2 diabetes in adults aged 18 and over.

What does Eversense 365 offer people with diabetes?

As the world's only One Year CGM, Eversense 365 offers people a truly differentiated CGM experience. Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal disruption, enabling confident decisions, long-term peace of mind, and enhanced quality of life with just one CGM.

- **Longest lasting CGM:** The only CGM that lasts for a year, while traditional 10-14 day CGMs tend to fail early.^{i,ii,iii}
- **No more wasted CGMs:** The removable* smart transmitter can be taken off when needed. If the transmitter gets knocked off, simply put it back on without wasting a CGM.
- **Trusted alerts:** Eversense 365 has exceptional accuracy over one year, with almost no compression lows and false alerts when sleeping^{iv}
- **Maximum comfort:** The gentle, silicone-based adhesive that can be changed daily and causes almost no skin reactions^v

How is Eversense 365 different to other CGMs?

As a One Year CGM, Eversense 365 is highly differentiated from traditional short-term CGMs. The tiny sensor rests comfortably under the skin for a full year, providing exceptional accuracy over one year, so that people can focus on managing their diabetes and not their CGM. It is designed to help minimize the device frustrations people experience with traditional short-term CGMs:

- CGMs stop working before the indicated 10-14 day wear time, wasting time and money
- Unexpected disruptions from CGMs getting knocked off
- Disruptive false alerts, including at night
- Skin irritation or discomfort from harsh adhesives

Who can use the Eversense 365 CGM system?

Eversense 365 is a CGM system indicated for the management of type 1 and type 2 diabetes in adults aged 18 years and older. The system is a prescription device indicated for use to replace fingerstick blood glucose measurements for diabetes treatment decisions.

Where is Eversense 365 available?

Eversense 365 has been cleared by the U.S. Food and Drug Administration (FDA) and is available for use in the U.S. Subject to regulatory approval in Europe, the system will later become available in selected markets. The Eversense E3 CGM system is currently available in the U.S., Germany, Italy, Spain, Sweden, Poland and Switzerland.



When was Eversense 365 made available?

Eversense 365 received U.S. Food and Drug Administration (FDA) clearance on September 17, 2024 and commercial launch began in the U.S. on October 1, 2024.

Is Eversense 365 covered by insurance in the U.S.?

Eversense 365 is widely available in the U.S. by insurance for people with diabetes taking insulin. Eversense 365 is covered by most commercial health plans and Ascensia is continuously working to broaden access as widely as possible to the product's unique benefits.

What is the Eversense PASS program?

This is a new Payment Assistance and Simple Savings (PASS) program. Under the Eversense PASS program, eligible individuals will pay as little as \$199 out of pocket for a full year of continuous glucose monitoring^{vi}.

Is Eversense 365 available for patients with Medicare?

Yes, Eversense 365 is available for patients with Medicare. Speak to an Eversense Expert for more information on Medicare Coverage.

What is the difference between Eversense 365 and Eversense E3?

Eversense 365 is indicated for up to one year while Eversense E3 is indicated for up to 6 months. Eversense E3 requires once daily calibration after day 21, whilst Eversense 365 requires once weekly calibration after day 13.

Eversense 365 retains all the unique features that Eversense users currently benefit from with Eversense E3, with both systems supporting people with diabetes to live life with minimal interruption. Both are long-term CGMs with fully implantable sensors.

Is Eversense E3 still available in the U.S.?

Yes. Eversense E3 is still available in the U.S.

Can Eversense 365 be integrated as part of an automated insulin delivery system?

Eversense 365 has been cleared as an integrated CGM (iCGM) system, indicating that it can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system. Eversense is exceptionally well suited to address common limitations^{vii} of AID systems and the companies are advancing partnership discussions with various pump manufacturers. At this point in time Eversense 365 does not have pump integration but we will keep everyone informed as we work towards this.

How does the Eversense sensor get inserted?

The tiny Eversense sensor rests comfortably under the skin after being inserted by a healthcare professional during a short in-office procedure. The insertion/removal area is treated with a local anesthetic (lidocaine) and then the sensor is inserted in the upper arm. The insertion and removal process usually takes approximately just five minutes and 84% of surveyed users would choose to be inserted again.

Do Eversense 365 users need to calibrate?

Eversense 365 requires once-weekly calibrations^{viii} after day 13, allowing patients to benefit from the system's exceptional accuracy and have unrivalled confidence in their glucose readings.

How does Eversense 365 work?

Eversense 365 consists of three main components: an implantable fluorescent glucose sensor, a removable* smart transmitter, and a mobile app to display the glucose data. The smart



transmitter wirelessly powers the sensor. The sensor measures glucose levels with its patented fluorescent technology, before digitalizing the data and sending it to the smart transmitter. The smart transmitter then calculates the glucose value, direction, and rate of change and sends the information to be viewed on the mobile app.

Who is responsible for Eversense?

Eversense CGMs are developed by Senseonics and brought to people with diabetes by Ascensia Diabetes Care, the exclusive global distribution partner.

How can people get started with Eversense?

Potential Eversense users can go to www.eversensecgm.com to learn more. Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at <https://www.ascensidiabetes.com/eversense/become-a-provider/>. Alternatively, contact 844-SENSE4U (736-7348) to learn more about the first and only long-term implantable CGM system.

* There is no glucose data generated when the transmitter is removed.

ⁱ Senseonics. (2024) Eversense 365 User Guide.

ⁱⁱ Abbott. (2024) Freestyle Libre 3 User Guide ART49385-001 Rev. A 04/24

ⁱⁱⁱ Dexcom (2024) G7 User Guide AW00078-10 Rev 003 MT-00078-10

^{iv} Christiansen MP, Klaff LJ, Brazg R, et al. (2018) A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. *Diabetes Technol Ther.* 20(3):197-206. doi:10.1089/dia.2017.0142

^v Deiss, D. et al. (2020). Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: A post-market registry study. *Diabetes Technology & Therapeutics*, 22(1), 48–52.

^{vi} Offer does not apply to the insertion and removal procedures. The Eversense PASS Program has limitations on eligibility. See [website](#) for more details. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. There is a maximum payment of \$2,500 per transaction for the program. There may be instances in which patient out-of-pocket costs exceed what is detailed in the offer. Eversense E3 is no longer eligible for the PASS Program.

^{vii} Sherr JL, Heinemann L, Fleming GA, et al. (2023) Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. *Diabetologia*. 66(1):3-22. doi:10.1007/s00125-022-05744-z

^{viii} After the initial 13-day warm-up period